Regulation of paxillin-p130-PI3K-AKT signaling axis by Src and PTPRT impacts colon tumorigenesis

Protein tyrosine phosphatase receptor T (PTPRT) is frequently mutated in a variety of human cancers including colorectal cancer. Here we report that PTPRT knockout increases the size of mouse colon tumors in the Apcmin+/− genetic background, suggesting that inactivation of PTPRT promotes tumor progression. We previously demonstrated that PTPRT dephosphorylates paxillin at tyrosine-Y88 residue. Consistently, phosphorylation of Y88 paxillin (pY88) is up-regulated in colon tumors derived from Apcmin+/− Ptprt−/− mice. An important downstream effector of pY88 paxillin is the oncogene Akt. Here, we show that pY88 paxillin impacts the Akt pathway by regulating the interaction between p130cas and the p85 regulatory subunit of PI3-Kinase. Additionally, while pY88 paxillin is a substrate of the tumor suppressor phosphatase PTPRT, the corresponding kinase has not been previously identified. In this study, we demonstrate that the oncogenic kinase Src directly phosphorylates paxillin at Y88. Moreover, colorectal cancer cells that express high levels of pY88 paxillin are sensitive to dasatinib treatment, suggesting that pY88 paxillin may serve as a predictive biomarker for Src family kinase inhibitors.

[1]  Zhenghe Wang,et al.  Genetic alterations of protein tyrosine phosphatases in human cancers , 2014, Oncogene.

[2]  Kelsey P. Pendleton,et al.  Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer , 2014, Proceedings of the National Academy of Sciences.

[3]  Yujun Hao,et al.  Targeting the Protein–Protein Interaction between IRS1 and Mutant p110α for Cancer Therapy , 2014, Toxicologic pathology.

[4]  A. Lane,et al.  Control of Glutamine Metabolism By the Tumor Suppressor Rb , 2013, Oncogene.

[5]  S. McCall,et al.  Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer , 2014, Investigational New Drugs.

[6]  Huanming Yang,et al.  Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation , 2013, Nature Genetics.

[7]  S. Markowitz,et al.  Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functions. , 2013, Cancer cell.

[8]  A. McKenna,et al.  Exome and whole genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity , 2013, Nature Genetics.

[9]  Dennis C. Sgroi,et al.  Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes , 2016 .

[10]  Jing Pan,et al.  Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing. , 2012, Carcinogenesis.

[11]  C. Turner,et al.  Diverse roles for the paxillin family of proteins in cancer. , 2012, Genes & cancer.

[12]  Bin Tean Teh,et al.  Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes , 2012, Nature Genetics.

[13]  J. Montero,et al.  Inhibition of Src Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors , 2011, Clinical Cancer Research.

[14]  S. Davis,et al.  Exome sequencing identifies GRIN2A as frequently mutated in melanoma , 2011, Nature Genetics.

[15]  T. Hunter,et al.  Protein kinase signaling networks in cancer. , 2011, Current opinion in genetics & development.

[16]  S. Brady-Kalnay,et al.  Characterization of the Adhesive Properties of the Type IIb Subfamily Receptor Protein Tyrosine Phosphatases , 2010, Cell communication & adhesion.

[17]  Kishore Guda,et al.  Identification and functional characterization of paxillin as a target of protein tyrosine phosphatase receptor T , 2010, Proceedings of the National Academy of Sciences.

[18]  S. Brady-Kalnay,et al.  Cancer-Derived Mutations in the Fibronectin III Repeats of PTPRT/PTPρ Inhibit Cell-Cell Aggregation , 2010, Cell communication & adhesion.

[19]  Yu Xue,et al.  GPS 2.0, a Tool to Predict Kinase-specific Phosphorylation Sites in Hierarchy *S , 2008, Molecular & Cellular Proteomics.

[20]  C. Turner,et al.  Paxillin comes of age , 2008, Journal of Cell Science.

[21]  Susann M Brady-Kalnay,et al.  Tumor-Derived Extracellular Mutations of PTPRT/PTPρ Are Defective in Cell Adhesion , 2008, Molecular Cancer Research.

[22]  Z. Weng,et al.  Epitope tagging of endogenous proteins for genome-wide ChIP-chip studies , 2008, Nature Methods.

[23]  K. Kinzler,et al.  Identification of STAT3 as a substrate of receptor protein tyrosine phosphatase T , 2007, Proceedings of the National Academy of Sciences.

[24]  N. Tonks,et al.  Protein tyrosine phosphatases: from genes, to function, to disease , 2006, Nature Reviews Molecular Cell Biology.

[25]  C. Ko,et al.  Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. , 2005, Journal of the National Cancer Institute.

[26]  Giovanni Parmigiani,et al.  Mutational Analysis of the Tyrosine Phosphatome in Colorectal Cancers , 2004, Science.

[27]  M. Toosarvandani,et al.  Src-dependent association of Cas and p85 phosphatidylinositol 3'-kinase in v-crk-transformed cells. , 2003, Molecular cancer research : MCR.

[28]  M. Young,et al.  Protein phosphatase‐2A restricts migration of Lewis lung carcinoma cells by modulating the phosphorylation of focal adhesion proteins , 2003, International journal of cancer.

[29]  Michael D Schaller,et al.  Paxillin: a focal adhesion-associated adaptor protein , 2001, Oncogene.

[30]  G. Nemerow,et al.  Association of p130CAS with Phosphatidylinositol-3-OH Kinase Mediates Adenovirus Cell Entry* , 2000, The Journal of Biological Chemistry.

[31]  C. Turner,et al.  Characterization of Tyrosine Phosphorylation of Paxillin in Vitro by Focal Adhesion Kinase (*) , 1995, The Journal of Biological Chemistry.